Global Tricuspid Regurgitation Market Growth (Status and Outlook) 2025-2031

The global Tricuspid Regurgitation market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

Tricuspid regurgitation, or tricuspid valve regurgitation, is a type of heart valve disease that occurs when the valve's flaps (cusps or leaflets) do not close properly. The tricuspid valve controls the flow of blood from your heart's right atrium (top chamber) to the right ventricle (bottom chamber).

Key Features

United States market for Tricuspid Regurgitation is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Tricuspid Regurgitation is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Tricuspid Regurgitation is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Segmentation by Type

• Tricuspid Valve Replacement
• Tricuspid Valve Repair

Segmentation by Application

• Primary Tricuspid Regurgitation
• Functional Tricuspid Regurgitation

Market by Region

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

Company Coverage

• Abbott
• Mitralign
• Medtronic
• Boston Scientific
• Mitralix
• Venus Medtech
• NeoChord
• Gore Medical
• Valtech Cardio
• Neovasc
• Peijia Medical

Key Questions Addressed in this Report